title: Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy.
abstract: Eight patients with epithelial ovarian carcinoma persisting after chemotherapy, selected for having a residual tumor no larger than 1 cm in diameter, were treated intra-peritoneally (i.p.) with recombinant interferon-gamma twice weekly for 3 months. Toxicity consisted of fever and malaise in all patients and a transient rise in hepatic enzyme levels in 3 patients. The cytotoxic function of peripheral blood and peritoneal tumor-associated lymphocytes (TAL) and macrophages (TAM), was studied using cell lines as targets. I.p. IFN-gamma augmented the cytotoxic activity of lymphocytes and mononuclear phagocytes: stimulation was more marked and more frequently observed with TAL and occasionally TAM than with blood effectors, suggesting preferential modulation at the site of tumor growth and IFN administration. Surgical laparotomy revealed that 1 patient had a complete response, 2 a partial response and 2 had stable disease, while 3 patients had progressive disease. In this small series of patients there was no obvious, strict correlation between immunomodulation by IFN-gamma and clinical response. These results indicate that, in contrast to its lack of activity in advanced ovarian carcinoma, IFN-gamma has definite immunomodulatory and antitumor activity in the presence of limited tumor burden.
authors.affiliation: Dept. of Obstetrics and Gynecology, University of Milan, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Colombo
authors.forename: F
authors.initials: F
authors.lastname: Peccatori
authors.forename: C
authors.initials: C
authors.lastname: Paganin
authors.forename: S
authors.initials: S
authors.lastname: Bini
authors.forename: M
authors.initials: M
authors.lastname: Brandely
authors.forename: C
authors.initials: C
authors.lastname: Mangioni
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
authors.forename: P
authors.initials: P
authors.lastname: Allavena
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000009:adverse effects; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D014407:Tumor Cells, Cultured
chemical_list: D007371:Interferon-gamma